Holen Sie sich die Stockscreener-App
9.82
1.97%
0.19
Vorhandelsmarkt:
9.88
0.06
+0.61%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$9.63
Offen:
$9.75
24-Stunden-Volumen:
6.78M
Relative Volume:
1.54
Marktkapitalisierung:
$1.60B
Einnahmen:
$1.08B
Nettoeinkommen (Verlust:
$422.82M
KGV:
4.307
EPS:
2.28
Netto-Cashflow:
$-637.33M
1W Leistung:
+19.76%
1M Leistung:
+43.78%
6M Leistung:
+31.46%
1J Leistung:
+5.36%
1-Tages-Spanne:
$9.615
$10.20
1-Wochen-Bereich:
$8.20
$10.20
52-Wochen-Spanne:
$5.01
$10.64
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Vergleichen Sie NVAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.82 | 1.56B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Eingeleitet | Citigroup | Sell |
| 2025-02-28 | Eingeleitet | BTIG Research | Buy |
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
Pfizer Reshapes Pipeline With Novavax Deal And ViiV Exit - simplywall.st
Responsive Playbooks and the NVAX Inflection - Stock Traders Daily
Why Is Pfizer Stock Rising Tuesday? - Benzinga
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - The Motley Fool
What's Driving the Market Sentiment Around Novavax Inc? - Benzinga
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
MRNA vs NVAX: Which vaccine stock is Wall Street more bullish on right now? - MSN
Novavax (NASDAQ:NVAX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Decliners Report: Is Novavax Inc a play on infrastructure spendingRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals - Yahoo Finance
Novavax grants license for use of Matrix-M adjuvant to Pfizer - MSN
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus - Sahm
Key facts: Novavax signs $30M deal with Pfizer; shares rise 19.7% - TradingView — Track All Markets
Novavax, Inc.'s (NASDAQ:NVAX) Price Is Right But Growth Is Lacking After Shares Rocket 46% - 富途牛牛
Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality - marketscreener.com
NVAX Stock Rises Pre-Market As Pfizer Licenses Its Vaccine Technology - Stocktwits
Analysts Favor Novavax Over Moderna After $30M Pfizer Licensing Deal - Intellectia AI
The Bull Case For Pfizer (PFE) Could Change Following Novavax Matrix-M Adjuvant Licensing DealLearn Why - simplywall.st
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? - Stocktwits
Why Are Novavax (NVAX) Shares Soaring Today - The Globe and Mail
Novavax Strikes Major Deal with Pfizer, Surge in Stock Likely - StocksToTrade
Traders Buy Large Volume of Call Options on Novavax (NASDAQ:NVAX) - MarketBeat
Novavax Strikes $500M Licensing Deal with Pfizer for Matrix-M Technology - timothysykes.com
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
Here's Why Pfizer Is Willing To Pay $500 Million For Novavax's Matrix-M (NASDAQ:NVAX) - Seeking Alpha
Pfizer and Novavax ink $530m vaccine delivery licensing deal - Yahoo Finance
Novavax licenses Matrix-M adjuvant to Pfizer in deal worth up to $530 million By Investing.com - Investing.com South Africa
Novavax inks license agreement with Pfizer - The Pharma Letter
Novavax signs licensing agreement with Pfizer for vaccine development - Reuters
Assessing Novavax (NVAX) Valuation After Pfizer Matrix M Licensing Deal - Yahoo Finance
Novavax (NASDAQ:NVAX) Stock Price Up 8%Still a Buy? - MarketBeat
Novavax Licenses Rights to Key Vaccine Component to Pfizer - The Wall Street Journal
Pfizer Novavax Matrix M Deal Adds New Angle To Vaccine Story - simplywall.st
Novavax’s Adjuvant Licensing Strategy Continues With Pfizer Pact - Citeline News & Insights
BTIG Reiterates Buy Rating for NVAX with $19 Price Target | NVAX Stock News - GuruFocus
Novavax licenses Matrix-M adjuvant to Pfizer in deal worth up to $530 million - Investing.com Canada
Novavax Pops on Pfizer Licensing Deal - GuruFocus
Novavax's (NVAX) Buy Rating Reiterated at BTIG Research - MarketBeat
Novavax Stock Pops After Pfizer Licensing Agreement - Schaeffer's Investment Research
Novavax strikes deal with Pfizer for immune-boosting tech worth up to $530M - The Business Journals
Novavax Strikes License Deal With Pfizer for Use of Matrix-M Adjuvant - marketscreener.com
Novavax, Inc. Enters into A License and Option Agreement with Pfizer Inc - marketscreener.com
Novavax (NVAX) Surges on Licensing Deal with Pfizer - GuruFocus
Novavax rises on licensing deal with Pfizer (NVAX:NASDAQ) - Seeking Alpha
Investor Outlook: Novavax, Inc. (NVAX) Shows Potential 59.66% Upside Despite Challenges - DirectorsTalk Interviews
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):